Call Prep: Violetta Ostafin (Acrew Capital)
TL;DR
Violetta is a healthcare operating executive (CVS/Aetna CSO, Aon Global COO) now advising at Acrew Capital. She evaluates from an operator's lens — does this actually work? Will buyers buy it? Lead with Premera execution and the clinical workflow, not the AI. She's been the buyer. Speak to her as a peer, not a pitch target.
Her Profile in 30 Seconds
- Former EVP & Chief Strategy Officer at CVS Health (which owns Aetna)
- Former Global COO of Aon Health Solutions (~$2B business, 7K people)
- BCG consulting background — expects structured thinking
- Now: Venture Advisor at Acrew Capital (health sector) + runs her own advisory firm (VVO Advisors)
- Lauder/Wharton alumni — shared network with Michael
Investor Type: Healthcare Operator
Based on our investor segmentation, she's closest to a healthcare specialist but with an operator's evaluation frame (not a pure VC lens). Expect questions about:
- How the product actually works in a clinical workflow
- Whether nurses will adopt it
- Whether health plans will actually buy it (she's been the buyer)
- Operational scalability — can you do this across multiple payers?
She will NOT need healthcare 101. Go deep immediately.
Likely Questions & Best Answers
1. "Walk me through how this actually works for a nurse" (HIGH probability)
Best answer: Walk through the UM review workflow — case comes in, nurse needs to evaluate medical necessity against criteria, our AI surfaces the relevant criteria, clinical evidence, and recommendation. The nurse reviews and decides. We're the analytical layer, not the decision-maker.
Why she'll ask: She's an operator. She wants to see the workflow, not the tech.
2. "How did you get Premera? How's it going?" (HIGH probability)
Best answer: Wharton network → head actuary → head analytics → embedded team. We're on their 12-initiative AI roadmap, building case-by-case trust. Use the Refract version of this story (strong, detailed).
Why she'll ask: Proof of execution. A named payer client means everything to someone who's been inside a payer.
3. "What's the revenue model?" (HIGH probability)
Best answer: Use the Tau framework — SaaS platform fee (5-10%) + implementation on a rate card (discount to Palantir) + ongoing maintenance/licensing (~50-60% of contract). The implementation portion shrinks as a % with each new client because the core platform is reusable.
Why she'll ask: BCG brain. She'll want the economics to make sense structurally.
4. "How do you scale this beyond one client?" (MEDIUM probability)
Best answer: The core analytical layer — criteria matching, clinical evidence extraction, recommendation engine — is reusable. Implementation is payer-specific (data integration, workflow customization, team training). Each new payer is faster than the last. Think Palantir: same platform, different deployments.
Why she'll ask: She ran a 7K-person global operation. She thinks about scale.
5. "Who else is doing this?" (MEDIUM probability)
Best answer: Have the competitive landscape ready (Charter Health, Optera, Latitude, Otter Health, MCG/InterQual as incumbents). Our differentiation: we're embedded as the deployment partner, not selling software over the wall.
Why she'll ask: BCG-trained → competitive positioning is instinctive.
6. "What do you need from an investor?" (MEDIUM probability)
Best answer: Healthcare buyer introductions. Someone who can open doors at health plans and validate our approach from the inside. Violetta specifically has this — lean into it.
Why she'll ask: She knows her value as an operator-advisor. She wants to know if you know it too.
What to Lead With
Open with the problem, not the product. Violetta has lived inside the organizations that suffer from broken UM workflows. Start with:
- "You've seen this from the inside at CVS/Aetna — UM review is still mostly manual, nurses are burning out, and payers are spending billions on a process that hasn't fundamentally changed."
- Then: "We're embedded at Premera as their AI engineering team for clinical operations. We started with UM because it's the highest-volume, most painful workflow."
This positions the conversation as peer-to-peer, not pitch-to-investor.
What to Avoid
- Don't oversell the AI. She's seen vaporware at CVS scale. Show the product working, not the vision of what it could be.
- Don't explain healthcare to her. She knows more about payer operations than we do. Match her depth.
- Don't treat this as "just an investor call." She may be more valuable as a strategic advisor than as a check-writer (she's an advisor at Acrew, not a partner). Explore that angle.
Demo Strategy
Show it if possible. Violetta is an operator — she'll want to see the product. But frame the demo around the nurse workflow, not the technology. "Here's what a nurse sees when a case comes in..." not "Here's our AI architecture."
Make sure the demo URL works. No localhost.
Strategic Angle
Even if Acrew doesn't invest, Violetta is extraordinarily valuable as:
- Payer buyer validator — she was CSO at CVS/Aetna
- GTM advisor — she literally advises healthcare companies on commercialization
- Connector — CVS, Aon, BCG networks are deep in our target buyer universe
- Acrew deal champion — she can bring us to a partner if she's convinced
Play for the relationship, not just the check.
Answer Gaps to Watch For
From our synthesis, these are areas where we've been weak before:
- Market size / TAM — have numbers ready if she asks (BCG brain = will want sizing)
- Competitive differentiation — she'll pattern-match against what she's seen. Have the "why us" crisp.
- Written materials — she has the deck. If she references the "wrapper" impression, use the Tau reframe: "The way we pitch to customers is different than VCs — we're not a wrapper, we're the deployment partner."
Last updated: Feb 12, 2026